Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Apr;37(4):375–381. doi: 10.1111/j.1365-2125.1994.tb04292.x

Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.

L A Bauer 1, T O'Sullivan 1, W G Reiss 1, J R Horn 1, K Opheim 1, D E Strandness 1, R L Carithers 1
PMCID: PMC1364739  PMID: 8018459

Abstract

Duplex scanning was used to measure liver blood flow (hepatic artery and main branches of the portal and hepatic veins) in six healthy subjects, five cirrhotic patients, and six hepatitis patients. Antipyrine clearance and formation clearances to its metabolites were also measured. Compared with healthy control subjects, cirrhotic patients had a lower hepatic vein blood flow (-76%, P < 0.05). This was due primarily to a lower portal vein blood flow (-36%, NS). A statistically significant difference in liver blood flow between patients with hepatitis and normal subjects was not detected. Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were significantly different in cirrhotic patients compared with the healthy subjects (mean +/- s.d.-healthy controls: t1/2 = 13.7 +/- 3.0 h, CL = 30.0 +/- 8.6 ml h-1 kg-1, AUC = 549 +/- 139 mg l-1 h; cirrhotic patients: t1/2 = 32.4 +/- 1.7 h, CL = 12.3 +/- 2.1 ml h-1 kg-1, AUC = 1061 +/- 218 mg l-1 h; P < 0.008). Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were not significantly different in hepatitis patients compared with the healthy subjects (hepatitis patients: t1/2 = 14.3 +/- 3.7 h, CL = 29.3 +/- 8.5 ml h-1 kg-1, AUC = 498 +/- 142 mg l-1 h). The volume of distribution of antipyrine was similar in all three groups of subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
375

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. B., Ranek L., Statland B. E., Tygstrup N. Clearance of antipyrine-dependence of quantitative liver function. Eur J Clin Invest. 1974 Apr;4(2):129–134. doi: 10.1111/j.1365-2362.1974.tb00383.x. [DOI] [PubMed] [Google Scholar]
  2. BRADLEY S. E., INGELFINGER F. J., BRADLEY G. P. Hepatic circulation in cirrhosis of the liver. Circulation. 1952 Mar;5(3):419–429. doi: 10.1161/01.cir.5.3.419. [DOI] [PubMed] [Google Scholar]
  3. Bauer L. A., McDonnell N., Horn J. R., Zierler B., Opheim K., Strandness D. E., Jr Single and multiple doses of oral cimetidine do not change liver blood flow in humans. Clin Pharmacol Ther. 1990 Aug;48(2):195–200. doi: 10.1038/clpt.1990.135. [DOI] [PubMed] [Google Scholar]
  4. Branch R. A., James J. A., Read A. E. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease. Clin Pharmacol Ther. 1976 Jul;20(1):81–89. doi: 10.1002/cpt197620181. [DOI] [PubMed] [Google Scholar]
  5. CAESAR J., SHALDON S., CHIANDUSSI L., GUEVARA L., SHERLOCK S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci. 1961 Aug;21:43–57. [PubMed] [Google Scholar]
  6. Danhof M., Breimer D. D. Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol. 1979 Dec;8(6):529–537. doi: 10.1111/j.1365-2125.1979.tb01040.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Danhof M., Groot-van der Vis E., Breiner D. D. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology. 1979;18(4):210–223. doi: 10.1159/000137254. [DOI] [PubMed] [Google Scholar]
  8. Danhof M., van Zuilen A., Boeijinga J. K., Breimer D. D. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur J Clin Pharmacol. 1982;21(5):433–441. doi: 10.1007/BF00542332. [DOI] [PubMed] [Google Scholar]
  9. Horn J. R., Zierler B., Bauer L. A., Reiss W., Strandness D. E., Jr Estimation of hepatic blood flow in branches of hepatic vessels utilizing a noninvasive, duplex Doppler method. J Clin Pharmacol. 1990 Oct;30(10):922–929. doi: 10.1002/j.1552-4604.1990.tb03572.x. [DOI] [PubMed] [Google Scholar]
  10. Klotz U., Fischer C., Müller-Seydlitz P., Schulz J., Müller W. A. Alterations in the disposition of differently cleared drugs in patients with cirrhosis. Clin Pharmacol Ther. 1979 Aug;26(2):221–227. doi: 10.1002/cpt1979262221. [DOI] [PubMed] [Google Scholar]
  11. LEEVY C. M., MENDENHALL C. L., LESKO W., HOWARD M. M. Estimation of hepatic blood flow with indocyanine green. J Clin Invest. 1962 May;41:1169–1179. doi: 10.1172/JCI104570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. O'Sullivan T. A., Bauer L. A., Horn J. R., Zierler B. K., Strandness D. E., Jr, Williams-Warren J., Smith A. L., Unadkat J. D. Disposition of drugs in cystic fibrosis. II. Hepatic blood flow. Clin Pharmacol Ther. 1991 Oct;50(4):450–455. doi: 10.1038/clpt.1991.163. [DOI] [PubMed] [Google Scholar]
  13. Park B. K., Kitteringham N. R. Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications. Xenobiotica. 1990 Nov;20(11):1171–1185. doi: 10.3109/00498259009046837. [DOI] [PubMed] [Google Scholar]
  14. Pessayre D., Lebrec D., Descatoire V., Peignoux M., Benhamou J. P. Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology. 1978 Mar;74(3):566–571. [PubMed] [Google Scholar]
  15. Poulsen H. E., Loft S. Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J Hepatol. 1988 Jun;6(3):374–382. doi: 10.1016/s0168-8278(88)80057-6. [DOI] [PubMed] [Google Scholar]
  16. Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646–649. doi: 10.1002/bjs.1800600817. [DOI] [PubMed] [Google Scholar]
  17. Reiss W. G., Bauer L. A., Horn J. R., Zierler B. K., Easterling T. R., Strandness D. E., Jr The effects of oral nifedipine on hepatic blood flow in humans. Clin Pharmacol Ther. 1991 Oct;50(4):379–384. doi: 10.1038/clpt.1991.154. [DOI] [PubMed] [Google Scholar]
  18. Rowland M., Benet L. Z., Graham G. G. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1973 Apr;1(2):123–136. doi: 10.1007/BF01059626. [DOI] [PubMed] [Google Scholar]
  19. Schellens J. H., Janssens A. R., van der Wart J. H., van der Velde E. A., Breimer D. D. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach. Eur J Clin Invest. 1989 Oct;19(5):472–479. doi: 10.1111/j.1365-2362.1989.tb00262.x. [DOI] [PubMed] [Google Scholar]
  20. Schellens J. H., van der Wart J. H., Danhof M., van der Velde E. A., Breimer D. D. Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Br J Clin Pharmacol. 1988 Oct;26(4):373–384. doi: 10.1111/j.1365-2125.1988.tb03394.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Teunissen M. W., Meerburg-van der Torren J. E., Vermeulen N. P., Breimer D. D. Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine. J Chromatogr. 1983 Dec 9;278(2):367–378. [PubMed] [Google Scholar]
  22. Teunissen M. W., Spoelstra P., Koch C. W., Weeda B., van Duyn W., Janssens A. R., Breimer D. D. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br J Clin Pharmacol. 1984 Nov;18(5):707–715. doi: 10.1111/j.1365-2125.1984.tb02533.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Teunissen M. W., Srivastava A. K., Breimer D. D. Influence of sex and oral contraceptive steroids on antipyrine metabolite formation. Clin Pharmacol Ther. 1982 Aug;32(2):240–246. doi: 10.1038/clpt.1982.154. [DOI] [PubMed] [Google Scholar]
  24. Wagner J. G. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm. 1976 Oct;4(5):443–467. doi: 10.1007/BF01062831. [DOI] [PubMed] [Google Scholar]
  25. Weber A., Opheim K., Smith A. L. Simplified high performance liquid chromatographic quantitation of antipyrine. J Chromatogr Sci. 1984 Jun;22(6):239–240. doi: 10.1093/chromsci/22.6.239. [DOI] [PubMed] [Google Scholar]
  26. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES